Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 dose-escalation study of [212Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer
ACTRN12622001378718Phase 2Recruiting
- Sponsor
- AdvanCell
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ADVC001 in prostate cancer (PCa) and prostate adenocarcinoma, sponsored by AdvanCell. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Incidence and severity of dose-limiting toxicities and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
ADVC001
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on ACTRN12622001378718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001378718.